Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
HIV Drugs Global Market Research Report 2023
March 27, 2023 10:28 ET
|
Research and Markets
Dublin, March 27, 2023 (GLOBE NEWSWIRE) -- The "HIV Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global HIV drug market is expected to grow from...
Insights on the HIV/AIDS Drugs Global Market to 2027 - Increasing R&D Initiatives for the Development of the Long-Acting Suppression Antiretroviral Therapy Presents Opportunities
September 14, 2022 07:43 ET
|
Research and Markets
Dublin, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The "Global HIV/AIDS Drugs Market (2022-2027) by Medication Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with...
Global and Historical Trends - HIV Epidemiology Forecasts to 2029
February 22, 2022 05:53 ET
|
Research and Markets
Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The total prevalent...
Human Immunodeficiency Virus Type-1 (HIV-1) Industry Landscape Report 2021-2030 Featuring Insights Into Lenacapavir (GS-6207), GSK3640254 (GSK'254), and MK-8591A (Islatravir/doravirine; DOR/ISL)
December 21, 2021 09:03 ET
|
Research and Markets
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus Type-1 (HIV-1) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
November 10, 2021 07:30 ET
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET
|
Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
Global HIV Drugs Market Report 2021-2030: Focus on NRT's, NNRT's, Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, & Chemokine Receptor Inhibitors
May 11, 2021 05:28 ET
|
Research and Markets
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players...
Global Human Immunodeficiency Virus (HIV) Therapeutics Drug Forecast and Market Analysis to 2029
March 10, 2021 08:23 ET
|
Research and Markets
Dublin, March 10, 2021 (GLOBE NEWSWIRE) -- The "Human Immunodeficiency Virus (HIV) Therapeutics - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's...
United States HIV Infection Drug Market Report 2021-2026: Success Rate Associated with the Available Anti-retrovirals are Continuing to Expand at Historic Levels
February 24, 2021 08:03 ET
|
Research and Markets
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report has been added to ResearchAndMarkets.com's offering. "US HIV...